 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > ImClone Systems Incorporated
 |
ImClone Systems Incorporated |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Argentine bonds surge, markets await IMF aid details Aug 22 2001 05:40 AM PDT
Asia Markets-Tokyo stocks cheer BOJ easing, currencies upbeat Aug 14 2001 03:56 AM PDT
ImClone loss widens on R&D spending Aug 14 2001 03:54 AM PDT
> More WIRE STORIES about this company
NEWS FROM THE STANDARD |
 |
Profiting From Invention
May 29 2000 12:00 AM PDT
PROFILE |
 |
ImClone Systems' drug candidates are of mice and men. It develops chimerized (made from mouse and human antibodies) treatments and vaccines for cancer. Germany's Merck KGaA and the firm are developing lead drug candidate IMC-C225, a growth factor inhibitor that may fight colorectal and head and neck cancers. ImClone is also developing other products, including cancer-related angiogenesis inhibitors, vaccines for small-cell lung cancer and melanoma, and endothelial stem cells to speed wound healing and muscle regeneration. The firm licenses its DNA-based diagnostics technology to Abbot Laboratories. Founding brothers Samuel and Harlan Waksal own more than 10% of ImClone.
COMPETITION |
 |
Abgenix, Inc. (ABGX)
Medarex, Inc. (MEDX)
OSI Pharmaceuticals, Inc. (OSIP)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 1.40
1-Yr. Sales Growth: (33.3)%
Employees: 272
Revenue per employee: $5,147.06
KEY PEOPLE |
 |
Samuel D. Waksal
CEO
Daniel S. Lynch
CFO
CONTACT INFO |
 |
180 Varick St.
New York, NY 10014
US
Phone: 212-645-1405
Fax: 212-645-2054
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |